Finland’s Orion Sues Sun Pharma Of India In U.S. Court In Patent Dispute
This article was originally published in PharmAsia News
Finland's Orion is suing India's Sun Pharma Global in the United States to protect its patent for the Comtan (entacapone) drug for Parkinson's disease. Sun has applied with U.S. FDA to market a generic version of the drug. Orion said it originated entacapone and has an exclusive license with Novartis to market Comtan in the U.S.. The suit puts Sun's application with the FDA on hold for as long as 30 months. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.